You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
|
|---|---|
| Published in |
Clinical Cancer Research, January 2017
|
| DOI | 10.1158/1078-0432.ccr-16-1543 |
| Pubmed ID | |
| Authors |
Heather A. Parsons, Julia A. Beaver, Ashley Cimino-Mathews, Siraj M. Ali, Jennifer Axilbund, David Chu, Roisin M. Connolly, Rory L. Cochran, Sarah Croessmann, Travis A. Clark, Christopher D. Gocke, Stacie C. Jeter, Mark R. Kennedy, Josh Lauring, Justin Lee, Doron Lipson, Vincent A. Miller, Geoff A. Otto, Gary L. Rosner, Jeffrey S. Ross, Shannon Slater, Philip J. Stephens, Dustin A. VanDenBerg, Antonio C. Wolff, Lauren E. Young, Daniel J. Zabransky, Zhe Zhang, Jane Zorzi, Vered Stearns, Ben H. Park |
| Abstract |
The clinical utility of next generation sequencing (NGS) in breast cancer has not been demonstrated.We hypothesized we could perform NGS of a new biopsy from patients with metastatic triple negative breast cancer (TNBC) in a clinically actionable timeframe. We planned to enroll 40 patients onto a prospective study, Individualized Molecular Analyses Guide Efforts (IMAGE),to evaluate the feasibility of obtaining a new biopsy of a metastatic site, perform NGS (FoundationOne{trade mark, serif}), and convene a molecular tumor board to formulate treatment recommendations within 28 days. We collected blood at baseline and at time of restaging to assess cell-free circulating plasma tumor DNA (ptDNA). We enrolled 26 women with metastatic TNBC who had received {greater than or equal to}1 line of prior chemotherapy, and 20 (77%) underwent NGS of a metastatic site biopsy.Twelve(60%) evaluable patients received treatment recommendations within 28 days of consent. The study closed after 20 patients underwent NGS, based on protocol-specified interim futility analysis.Three patients went on to receive genomically directed therapies. Twenty-four of 26 patients had genetic alterations successfully detected in ptDNA. Among 5 patients, 4 mutations found in tumor tissues were not identified in blood and 4 mutations found in blood were not found in corresponding tumors.In nine patients, NGS of follow up blood samples showed 100% concordance with baseline blood samples. This study demonstrates challenges of performing NGS on prospective tissue biopsies in patients with metastatic TNBC within 28 days, while also highlighting the potential use of blood as a more time efficient and less invasive method of mutational assessment. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| Switzerland | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 88 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 18% |
| Other | 12 | 13% |
| Student > Master | 12 | 13% |
| Student > Ph. D. Student | 8 | 9% |
| Student > Doctoral Student | 6 | 7% |
| Other | 16 | 18% |
| Unknown | 19 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 26% |
| Biochemistry, Genetics and Molecular Biology | 16 | 18% |
| Agricultural and Biological Sciences | 13 | 15% |
| Computer Science | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 10 | 11% |
| Unknown | 20 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2021.
All research outputs
#13,152,475
of 23,538,320 outputs
Outputs from Clinical Cancer Research
#9,215
of 12,762 outputs
Outputs of similar age
#213,507
of 452,549 outputs
Outputs of similar age from Clinical Cancer Research
#105
of 199 outputs
Altmetric has tracked 23,538,320 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,762 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,549 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 199 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.